Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group.

Novel treatment strategies are needed to improve cure for all children with acute lymphoblastic leukemia (ALL). To this end, we investigated the therapeutic potential of clofarabine in primary ALL in trial CoALL 08-09 (clinicaltrials gov. identifier: NCT01228331). The primary study objective was the...

Descripción completa

Detalles Bibliográficos
Autores principales: Escherich, Gabriele, zur Stadt, Udo, Borkhardt, Arndt, Dilloo, Dagmar, Faber, Jörg, Feuchtinger, Tobias, Imschweiler, Thomas, Jorch, Norbert, Pekrun, Arnulf, Schmid, Irene, Schramm, Franziska, Spohn, Michael, Zimmermann, Martin, Horstmann, Martin A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052901/
https://www.ncbi.nlm.nih.gov/pubmed/34348455
http://dx.doi.org/10.3324/haematol.2021.279357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052901/
https://www.ncbi.nlm.nih.gov/pubmed/34348455
http://dx.doi.org/10.3324/haematol.2021.279357

Ejemplares similares